- Report
- April 2024
- 95 Pages
Global
From €4699EUR$4,950USD£3,964GBP
- Report
- March 2025
- 174 Pages
Global
From €5316EUR$5,600USD£4,484GBP
- Report
- March 2025
- 297 Pages
Global
From €5174EUR$5,450USD£4,364GBP
- Report
- March 2025
- 93 Pages
Global
From €5316EUR$5,600USD£4,484GBP
- Report
- March 2025
- 93 Pages
Global
From €5316EUR$5,600USD£4,484GBP
- Report
- March 2025
- 82 Pages
Global
From €5316EUR$5,600USD£4,484GBP
- Report
- March 2025
- 197 Pages
Global
From €4699EUR$4,950USD£3,964GBP
- Report
- March 2025
- 199 Pages
Global
From €4699EUR$4,950USD£3,964GBP
- Report
- March 2025
- 196 Pages
Global
From €4699EUR$4,950USD£3,964GBP
- Report
- March 2025
- 188 Pages
Global
From €4699EUR$4,950USD£3,964GBP
- Report
- March 2025
- 182 Pages
Global
From €4699EUR$4,950USD£3,964GBP
- Report
- March 2025
- 194 Pages
Global
From €4699EUR$4,950USD£3,964GBP
- Report
- March 2025
- 194 Pages
Global
From €4699EUR$4,950USD£3,964GBP
- Report
- July 2024
- 175 Pages
Global
From €4747EUR$5,000USD£4,004GBP
- Report
- February 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- February 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- February 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- February 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- December 2024
- 175 Pages
Global
From €4747EUR$5,000USD£4,004GBP
- Report
- November 2024
- 175 Pages
Global
From €4747EUR$5,000USD£4,004GBP

The aortic valve replacement market is a segment within the broader field of cardiovascular devices that focuses on treatments for aortic valve disorders, such as aortic stenosis or aortic insufficiency. This market includes the development, manufacturing, and sale of prosthetic aortic valves intended to replace diseased or malfunctioning native valves in patients. Two primary types of valves are used in aortic valve replacements: mechanical valves, which are made from durable materials like titanium or carbon, and biological valves, which are made from tissue derived from animal sources or donated human hearts. With advancements in medical technology, the market has expanded to include less invasive procedures like transcatheter aortic valve replacement (TAVR), which allows for the placement of a new valve without the need for open-heart surgery. This market segment is driven by an aging population, the rising prevalence of heart valve diseases, and continued innovation in valve technologies and surgical techniques.
Among the companies that are key players in the aortic valve replacement market, some include Edwards Lifesciences, Medtronic, Boston Scientific, Abbott, and LivaNova. These companies are known for their contributions to the development of both transcatheter and surgical valve replacement technologies and their consistent efforts to improve patient outcomes through advancements in cardiovascular device engineering. Show Less Read more